<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03223961</url>
  </required_header>
  <id_info>
    <org_study_id>GFM-EPO-PRETAR</org_study_id>
    <nct_id>NCT03223961</nct_id>
  </id_info>
  <brief_title>A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS</brief_title>
  <acronym>EPO-PRETAR</acronym>
  <official_title>A Randomized Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS With Non RBC Transfusion Dependent Anemia and Without Del 5q</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Francophone des Myelodysplasies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Francophone des Myelodysplasies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, randomized, multicenter, phase III study

      Patients with baseline Hb comprised between 9 and 10.5g/dl will be randomized to receive EPO
      Alfa 60000 UI/week for at least 12 weeks:

        -  Either at diagnosis Or

        -  at the Hb threshold chosen for RBC transfusions (must be &lt; 9g/dl)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      in this trial we will compare the early introduction of EPO alfa to the delayed introduction
      in lower risk MDS with non RBC transfusion dependent anemia.

      At enrollment patients will be randomised in the 2 arms (early and delayed start of EPO
      alfa).

      Treatment Regimen Epoetin alfa 60000 UI/week for at least 12 weeks

        1. Early onset arm: early onset of EPO ALFA 60000 IU/week , at patient inclusion

        2. Delayed onset arm: late introduction of EPO ALFA 60000 IU/week, whenever the patient
           reaches the level chosen RBC transfusions (based on age, comorbidities, anticipated
           tolerance of anemia).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomazed study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to RBC transfusion dependence in non RBC transfusion dependent lower risk MDS patients with anemia with early (at inclusion of the patient) versus delayed onset,( at the threshold chosen for RBC transfusion) of EPO ALFA</measure>
    <time_frame>12 weeks</time_frame>
    <description>RBC transfusion dependence will be defined by requirement of at least transfusions of 2 PRBC within an interval of less than 8 weeks, given for Hb &lt;8g/dl or &lt;9g/dl according to comorbidities and in the absence of other cause of anemia (bleeding, surgery…), taking into account only transfusions given at least 12 weeks after onset of treatment with EPO ALFA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Erythroid response (according to IWG 2006 criteria)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Erythroid response (according to IWG 2006 criteria) after 12 weeks of EPO ALFA treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response duration to EPO ALFA</measure>
    <time_frame>4 years</time_frame>
    <description>response duration to EPO ALFA measured from the date of enrollment until failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>4 years</time_frame>
    <description>Overall survival measured from the date of enrollment to death or the date of last contact</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Early onset arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: early onset of Eprex60000 IU/week , at patient inclusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed onset arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: late introduction of Eprex60000 IU/week, whenever the patient reaches the level chosen RBC transfusions (based on age, comorbidities, anticipated tolerance of anemia).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPREX</intervention_name>
    <description>60 000 U/week for at least 12 weeks</description>
    <arm_group_label>Early onset arm</arm_group_label>
    <arm_group_label>Delayed onset arm</arm_group_label>
    <other_name>Epoetin alfa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years

          2. MDS according to WHO 2016 criteria, with low or int 1 classical IPSS

          3. Non-RBC transfusion dependent anemia

          4. Hb level between 9 and 10.5g/dl (at the center's lab)

          5. Hb level should be at least 1g/dl higher than the Hb threshold chosen to start RBC
             transfusions based on age, comorbidities and predicted clinical tolerance of anemia
             (this transfusion threshold should be chosen between 8 and 9g/dl)

          6. Serum EPO level &lt;500U/l

          7. No other cause of anemia (including iron deficiency, vitamin B12 or B9 deficiency,
             hemolysis, hypothyroidism….)

          8. Performance status &lt;=2

        Exclusion Criteria:

          1. Higher risk MDS (IPSS intermediate-2 or high)

          2. Del 5q

          3. Baseline Hemoglobin level &gt; 10.5 g/dl or &lt;9g/dl

          4. Transfusion threshold (based on age , comorbidities…) &gt;9g/dl

          5. Transfusion threshold less than 1 g/dl below baseline Hb level

          6. RBC transfusion dependence. Patients may have received only one transfusion series for
             MDS prior to inclusion

          7. CMML , if &gt;10 % BM blasts or WBC&gt;13.000/mm3

          8. Uncontrolled hypertension

          9. Uncontrolled cardiovascular disease including angina pectoris or cardiac failure

         10. Renal failure: Creatinine clearance&lt;40ml/min (using MDRD formula)

         11. Pregnancy (positive bettaHCG) or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sophie Park, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sophie Park, Prof</last_name>
    <phone>+33 (0)4 76 76 62 77</phone>
    <email>spark@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fatiha Chermat, CRA</last_name>
    <phone>+33 (0)1 71 20 70 59</phone>
    <email>fatiha.chermat-ext@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Berengere gruson, MD</last_name>
      <phone>+33322455985</phone>
      <email>gruson.berengere@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Berengere Gruson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Angers</name>
      <address>
        <city>Angers</city>
        <zip>49 000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvain THEPOT</last_name>
      <phone>+33 2 41 35 44 66</phone>
      <email>sylvain.thepot@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Sylvain Tepot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Avignon</name>
      <address>
        <city>Avignon</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bohrane Slama, MD</last_name>
      <phone>0432753132</phone>
      <email>bslama@ch-avignon.fr</email>
    </contact>
    <investigator>
      <last_name>Bohrane Slama, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de La Cote Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne Banos, MD</last_name>
      <phone>033559443832</phone>
      <email>abanos@ch-cotebasque.fr</email>
    </contact>
    <investigator>
      <last_name>Anne Banos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>9300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thorsten Braun, MD</last_name>
      <phone>+33148957057</phone>
      <email>thorsten.braun@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Thorsten Braun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Berthou, Prof</last_name>
      <phone>+33298223504</phone>
      <email>christianberthou@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>Christian Berthou, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphane Cheze, MD</last_name>
      <phone>+33231272360</phone>
      <email>cheze-s@chu-caen.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphane Cheze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benoit De RENZIS, MD</last_name>
      <phone>+33 4 73 75 00 66</phone>
      <email>bderenzis@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Benoit De RENZIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHSF Gilles de Corbeil</name>
      <address>
        <city>Corbeil-Essonnes</city>
        <zip>91100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Célia Salanoubat, MD</last_name>
      <phone>+33160903178</phone>
      <email>celia.salanoubat@ch-sud-francilien.fr</email>
    </contact>
    <investigator>
      <last_name>Célia Salanoubat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie Park, MD, PHD</last_name>
      <phone>+33 4 76 76 62 77</phone>
      <email>spark@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie Park, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier du Mans</name>
      <address>
        <city>Le Mans cedex</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kamel Laribi, MD</last_name>
      <phone>+33243434361</phone>
      <email>klaribi@ch-lemans.fr</email>
    </contact>
    <investigator>
      <last_name>Kamel Laribi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Vincent de Paul</name>
      <address>
        <city>Lille</city>
        <zip>59160</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Rose, MD</last_name>
      <phone>+33 20874532</phone>
      <email>rose.christian@ghicl.net</email>
    </contact>
    <investigator>
      <last_name>Christian Rose, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie-Pierre Gourin, MD</last_name>
      <phone>+33555056642</phone>
      <email>marie-pierre.gourin@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Marie-Pierre Gourin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Wattel, MD, PHD</last_name>
      <phone>+33 4 72 11 74 01</phone>
      <email>wattel@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Eric Wattel, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IPC</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Norbert Vey, prof</last_name>
      <phone>033 4 91 22 36 67</phone>
      <email>veyn@ipc.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Norbert Vey, prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre Peterlin, MD</last_name>
      <phone>+33 2 40 08 32 77</phone>
      <email>pierre.peterlin@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Peterlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Cluzeau, MD</last_name>
      <phone>+33492035844</phone>
      <email>cluzeau.t@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Thomas Cluzeau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital St Louis T4</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre Fenaux, PHD</last_name>
      <phone>+33 171207018</phone>
      <email>pierre.fenaux@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Fenaux, prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Joffre-Perpignan</name>
      <address>
        <city>Perpignan</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurence Sanhes, MD</last_name>
      <phone>+33468616448</phone>
      <email>laurence.sanhes@ch-perpignan.fr</email>
    </contact>
    <investigator>
      <last_name>Laurence Sanhes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sophie Dimicoli-Salazar</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie Dimicoli-Salazar, MD</last_name>
      <phone>+33557656511</phone>
      <email>sophie.dimicoli-salazar@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie Dimicoli-Salazar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose Miguel Torregrosa Diaz, MD</last_name>
      <phone>+33 5 48 44 30 29</phone>
      <email>jose-miguel.torregrosa-diaz@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Jose Miguel Torregrosa Diaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR d'Annecy</name>
      <address>
        <city>Pringy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascale Cony-Makhoul, MD</last_name>
      <phone>+33450636608</phone>
      <email>pconymakhoul@ch-annecy.fr</email>
    </contact>
    <investigator>
      <last_name>Pascale Cony-Makhoul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chantal HIMBERLIN, MD</last_name>
      <phone>003326783644</phone>
      <email>chimberlin@chu-reims.fr</email>
    </contact>
    <investigator>
      <last_name>Chantal HIMBERLIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stanislas Nimubona, MD</last_name>
      <phone>33299289521</phone>
      <email>stanislas.nimubona@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Stanislas Nimubona, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aspasia Stamatoulas, MD</last_name>
      <phone>+33 232082288</phone>
      <email>aspasia.stamatoullas@chb.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Aspasia Stamatoullas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de STRASBOURG</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shanti NATAJARAN-AME, MD</last_name>
      <phone>00 33 3 88 12 76 70</phone>
      <email>shanti.ame@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Shanti NATAJARAN-AME, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IUCT Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Odile Beyne-Rauzy, Prof</last_name>
      <phone>+33531156264</phone>
      <email>beynerauzy.odile@iuct-oncopole.fr</email>
    </contact>
    <investigator>
      <last_name>Odile Beyne-Rauzy, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Brabois</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Agnès Guerci-Bresler, MD</last_name>
      <phone>+33383153281</phone>
      <email>a.guerci@chru-nancy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2017</study_first_submitted>
  <study_first_submitted_qc>July 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myelodysplastic syndrome</keyword>
  <keyword>erythropoetin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

